Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Comparison of the Quantum Blue® Reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Influence of sample centrifugation on plasma platelet count and activated partial thromboplastin time using patient samples

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Uncarboxylated Matrix Gla-Protein: A Biomarker of Vitamin K Status and Cardiovascular Risk

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Abnormal routine blood tests as predictors of mortality in acutely admitted patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Oxidatively generated modifications to nucleic acids in vivo: Measurement in urine and plasma

    Research output: Contribution to journalReviewResearchpeer-review

  3. Plasma calprotectin is superior to serum calprotectin as a biomarker of intestinal inflammation in ulcerative Colitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Phosphatidylcholine and its relation to apolipoproteins A-1 and B changes after Roux-en-Y gastric bypass: a cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Background: Infliximab (IFX) is a monoclonal antibody used to treat patients with inflammatory bowel disease (IBD). For IFX therapeutic drug monitoring (TDM), the most commonly used analysis is enzyme-linked immunosorbent assays (ELISA) which do not allow results to be provided in real-time. The aim of this study was to compare the in-house ELISA (Promonitor IFX) with the much faster assay Quantum Blue® IFX (QB) for quantification of serum IFX concentration among IBD patients in maintenance IFX therapy. Methods: We studied 30 serum samples from outpatients in IFX maintenance therapy at Copenhagen University Hospital Hvidovre, Denmark. Samples were used to compare IFX measurements from Promonitor IFX with QB. Therapeutic intervals of <3 μg/mL, 3–7 μg/mL and >7 μg/mL were equally covered. Differences were evaluated using Bland-Altman plots and Student t-test. Correlation was evaluated using x,y-plot and Pearson's correlation coefficient. The intermediate imprecision (CV%) of QB was measured at two levels (3 μg/mL and 7 μg/mL). For qualitative comparison, weighted kappa statistics (κ) were determined after stratification of results by therapeutic interval. Results: Promonitor IFX and QB were strongly correlated (r = 0.92, p < 0.001). The mean difference between Promonitor IFX and QB was −0.57 μg/mL (p = 0.2). The CV% of QB was 16.3% at 3 μg/mL and 16.7% at 7 μg/mL. Classification of results according to therapeutic interval showed almost perfect agreement (κ = 0.81). Conclusions: QB is a suitable alternative to Promonitor IFX for TDM in patients treated with IFX for IBD. The results revealed a strong correlation between methods, in particular at lower IFX concentrations, representing the most interesting clinical range. When the samples were stratified according to the therapeutic interval, an almost perfect agreement between the methods was observed.

Original languageEnglish
JournalClinical Biochemistry
Volume74
Pages (from-to)73-75
Number of pages3
ISSN0009-9120
DOIs
Publication statusPublished - Dec 2019

    Research areas

  • Enzyme-linked immunosorbent assays, Inflammatory bowel diseases, Infliximab, Point-of-Care, Therapeutic drug monitoring

ID: 58276982